Sanofi Aventis DEUTSCHLAND GMBH loses appeal at CAFC
The outcome
For the foregoing reasons, we affirm the four final written decisions that determined unpatentability based on Steenfeldt-Jensen: IPR2018-01670, IPR2018-01676, IPR2018-01678, and IPR2019-00979. That conclusion moots the appeals from the final written decisions in IPR2018-01675 and IPR2019-00122, which involve no claims other than those already covered by the SteenfeldtJensen reviews. We affirm in Appeal Nos. 20-1871, 20- 2032, 20-2033, and 20-2159. We dismiss as moot the appeals in Appeal Nos. 20-2029 and 20-2034.
For the foregoing reasons, we affirm the four final written decisions that determined unpatentability based on Steenfeldt-Jensen: IPR2018-01670, IPR2018-01676, IPR2018-01678, and IPR2019-00979. That conclusion moots the appeals from the final written decisions in IPR2018-01675 and IPR2019-00122, which involve no claims other than those already covered by the SteenfeldtJensen reviews. We affirm in Appeal Nos. 20-1871, 20- 2032, 20-2033, and 20-2159. We dismiss as moot the appeals in Appeal Nos. 20-2029 and 20-2034.
posted by Lawrence B. Ebert at 4:16 PM
0 Comments:
Post a Comment
<< Home